Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy
Denis Duboc, MD, PhD*,*,
Christophe Meune, MD*,
Guy Lerebours, MD ,
Jean-Yves Devaux, MD, PhD*,
Guy Vaksmann, MD* and
Henri-Marc Bécane, MD*
* French Working Group of Heart Involvement in Myopathies Investigators, Paris, France
Servier Laboratories, Paris, France

View larger version (22K):
[in a new window]
|
Figure 1 Distribution of left ventricular ejection fraction (LVEF) in groups 1 and 2 at study entry, 36 months, and 60 months of follow-up. Corresponds to the difference in the number of patients with LVEF <45% in each group. Red circles = group 1 (initially assigned to perindopril); black circles = group 2 (initially assigned to placebo).
|
|
|